34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2

and any accompanying images. A copy of the written consent is available for review by the Editor of this journal Fig. 4 (abstract P683). See text for description Fig. 3 (abstract P683). See text for description Journal for ImmunoTherapy of Cancer Page 95 of 237 2019, 7(Suppl 1):283 P684 Highly efficient selection of tumor neoantigens improves therapeutic cancer vaccine efficacy Guilhem Richard, PhD, Gad Berdugo, MSc, MBA , Michael Princiotta, MS, PhD, Leonard Moise, PhD, Matthew Ardito, BA, Christine Boyle, Dominique Bridon, William Martin, BA MD, Anne de Groot, MD EpiVax Oncology, Providence, RI, United States; EpiVax, Inc., Providence,

[1]  R. Mole.  Whole body irradiation; radiobiology or medicine? , 1953, The British journal of radiology.

[2]  F. H. Schmidt,et al.  Estimation Procedures for Consecutive First Order Irreversible Reactions , 1974 .

[3]  Kendall A. Smith,et al.  Long term culture of tumour-specific cytotoxic T cells , 1977, Nature.

[4]  T. Springer,et al.  Monoclonal antibody to a novel lymphocyte function-associated antigen (LFA-1): mechanism of blockade of T lymphocyte-mediated killing and effects on other T and B lymphocyte functions. , 1981, Journal of immunology.

[5]  F. Ruscetti.  Biology of interleukin-2 , 1984, Survey of immunologic research.

[6]  K. Horgan,et al.  Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. , 1990, Journal of immunology.

[7]  J. Banchereau,et al.  GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells , 1992, Nature.

[8]  Z. Eshhar,et al.  Endowing T cells with antibody specificity using chimeric T cell receptors , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  Z. Eshhar,et al.  Functional assembly of chimeric T-cell receptor chains. , 1992, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[10]  T. Waldmann,et al.  The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Banchereau,et al.  Activation of human dendritic cells through CD40 cross-linking , 1994, The Journal of experimental medicine.

[12]  W. Benedict,et al.  Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Teague,et al.  Specific inhibition of T lymphocyte coactivation by triggering integrin beta 1 reveals convergence of beta 1, beta 2, and beta 7 signaling pathways. , 1996, Journal of immunology.

[14]  E. Jaffee,et al.  The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Lieping Chen,et al.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.

[16]  J. Blay,et al.  The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. , 1997, Cancer research.

[17]  A. Lawson,et al.  Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. , 1998, Journal of immunology.

[18]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[19]  J. Spychała.  Tumor-promoting functions of adenosine. , 2000, Pharmacology & therapeutics.

[20]  B. Blom,et al.  Down-regulation of the macrophage lineage through interaction with OX2 (CD200). , 2000, Science.

[21]  S. Pileri,et al.  Hodgkin's lymphoma: the pathologist's viewpoint. , 2002, Journal of clinical pathology.

[22]  H. Rammensee,et al.  Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding , 2002, The Journal of Immunology.

[23]  L. Trusolino,et al.  Scatter-factor and semaphorin receptors: cell signalling for invasive growth , 2002, Nature Reviews Cancer.

[24]  D. Green,et al.  The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. , 2002, Immunity.

[25]  E. Wherry,et al.  Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo , 2003, Nature Medicine.

[26]  M. Weller,et al.  Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. , 2003, Cancer research.

[27]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[28]  E. Ingulli,et al.  Development of a Novel Transgenic Mouse for the Study of Interactions Between CD4 and CD8 T Cells During Graft Rejection , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  Federico Garrido,et al.  MHC class I antigens, immune surveillance, and tumor immune escape , 2003, Journal of cellular physiology.

[30]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[31]  A. Bosserhoff,et al.  Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. , 2004, The Journal of investigative dermatology.

[32]  G. Tricot,et al.  Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. , 2004, American journal of clinical pathology.

[33]  D. Campana,et al.  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia , 2004, Leukemia.

[34]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[35]  Hongmei Shen,et al.  Gene delivery to dendritic cells facilitated by a tumor necrosis factor alpha-competing peptide. , 2004, Molecular immunology.

[36]  S. Demaria,et al.  Combining radiotherapy and immunotherapy: a revived partnership. , 2005, International journal of radiation oncology, biology, physics.

[37]  N. Kawashima,et al.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[39]  W. Blackwelder,et al.  Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer , 2005, Nature Medicine.

[40]  P. Friedl,et al.  Tuning immune responses: diversity and adaptation of the immunological synapse , 2005, Nature Reviews Immunology.

[41]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Tuveson,et al.  Ductal pancreatic cancer in humans and mice. , 2005, Cold Spring Harbor symposia on quantitative biology.

[43]  J. Palazzo,et al.  Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. , 2005, Human pathology.

[44]  M. Lesniak,et al.  An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. , 2006, Neuro-oncology.

[45]  A. Wolf,et al.  High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. , 2006, Molecular immunology.

[46]  D. Hargrave,et al.  Diffuse brainstem glioma in children: critical review of clinical trials. , 2006, The Lancet. Oncology.

[47]  A. Ohta,et al.  A2A adenosine receptor protects tumors from antitumor T cells , 2006, Proceedings of the National Academy of Sciences.

[48]  A. Friedman,et al.  Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. , 2006, Cancer research.

[49]  Juan F. García,et al.  Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. , 2006, Blood.

[50]  K. Rock,et al.  Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Allison,et al.  Checkpoint blockade in cancer immunotherapy. , 2007, Advances in immunology.

[52]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[53]  M. Lesniak,et al.  Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. , 2006, Journal of neurosurgery.

[54]  Qi Zhou,et al.  Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. , 2005, Human gene therapy.

[55]  Qi Zhou,et al.  A Tumor-Targeted Nanodelivery System to Improve Early MRI Detection of Cancer , 2006, Molecular imaging.

[56]  M. Seman,et al.  Extracellular NAD and ATP: Partners in immune cell modulation , 2007, Purinergic Signalling.

[57]  N. Binart,et al.  Reproductive role of prolactin. , 2007, Reproduction.

[58]  S. Robson,et al.  Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. , 2007, The American journal of pathology.

[59]  B. Warren,et al.  Modulation of CD103 Expression on Human Colon Carcinoma-Specific CTL1 , 2007, The Journal of Immunology.

[60]  M. Neurath,et al.  In vitro generation of CD4+CD25+ regulatory cells from murine naive T cells , 2007, Nature Protocols.

[61]  Josef M. Penninger,et al.  Spontaneous tumor rejection by cbl-b–deficient CD8+ T cells , 2007, The Journal of experimental medicine.

[62]  Bruce Stillman,et al.  Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. , 2007, Cancer cell.

[63]  P. Moss,et al.  Immunodeficiency and immunotherapy in multiple myeloma , 2007, British journal of haematology.

[64]  E. Kistner,et al.  c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. , 2007, Cancer research.

[65]  T. Schumacher,et al.  Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. , 2007, Blood.

[66]  F. Marincola,et al.  The immunologic constant of rejection. , 2008, Trends in immunology.

[67]  J. Sampson,et al.  Combating immunosuppression in glioma. , 2008, Future oncology.

[68]  Antoni Ribas,et al.  PET Imaging of Cancer Immunotherapy , 2008, Journal of Nuclear Medicine.

[69]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[70]  D. Sze,et al.  Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. , 2008, The Lancet. Oncology.

[71]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[72]  C. Grady,et al.  Including persons with HIV infection in cancer clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[74]  Dan R. Littman,et al.  Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria , 2009, Cell.

[75]  Thomas P Herringson,et al.  Convenient targeting of stealth siRNA-lipoplexes to cells with chelator lipid-anchored molecules. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[76]  A. Ohta,et al.  A2A Adenosine Receptor May Allow Expansion of T Cells Lacking Effector Functions in Extracellular Adenosine-Rich Microenvironments1 , 2009, The Journal of Immunology.

[77]  I. Pastan,et al.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains , 2009, Proceedings of the National Academy of Sciences.

[78]  D. Largaespada,et al.  De novo induction of genetically engineered brain tumors in mice using plasmid DNA. , 2009, Cancer research.

[79]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[80]  Antoine M. van Oijen,et al.  Analysis of kinetic intermediates in single-particle dwell-time distributions. , 2010, Biophysical journal.

[81]  R. Stephens,et al.  Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. , 2010, The Journal of clinical investigation.

[82]  C. Drake.  Prostate cancer as a model for tumour immunotherapy , 2010, Nature Reviews Immunology.

[83]  S. Morrison,et al.  Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. , 2010, Blood.

[84]  G. Freeman,et al.  Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection , 2010, Proceedings of the National Academy of Sciences.

[85]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[86]  Takashi Murakami,et al.  CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. , 2010, Gastroenterology.

[87]  J. Penninger,et al.  Essential Role of E3 Ubiquitin Ligase Activity in Cbl-b–Regulated T Cell Functions , 2011, The Journal of Immunology.

[88]  Aaron Fenster,et al.  Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans , 2011, Nature.

[89]  J. McNamara,et al.  Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[90]  P. Fisher,et al.  Tumor-Specific Imaging through Progression Elevated Gene-3 Promoter-Driven Gene Expression , 2010, Nature Medicine.

[91]  S. Rosenberg,et al.  Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice , 2011, Clinical Cancer Research.

[92]  Andreas Kjær,et al.  64Cu loaded liposomes as positron emission tomography imaging agents. , 2011, Biomaterials.

[93]  R. Gascoyne,et al.  Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[95]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[96]  S. Olivares,et al.  Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. , 2011, Cancer research.

[97]  S. H. van der Burg,et al.  Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha , 2011, Cancer Immunology, Immunotherapy.

[98]  B. Rini,et al.  Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. , 2011, Neuro-oncology.

[99]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[100]  G. Srikrishna.  S100A8 and S100A9: New Insights into Their Roles in Malignancy , 2011, Journal of Innate Immunity.

[101]  S. Petrini,et al.  Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing. , 2011, Cancer research.

[102]  F. Marincola,et al.  Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis , 2011, Journal of Translational Medicine.

[103]  S. Robson,et al.  Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. , 2011, Neoplasia.

[104]  M. Tsao,et al.  c-MET as a potential therapeutic target and biomarker in cancer , 2011, Therapeutic advances in medical oncology.

[105]  Weiqing Jing,et al.  Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[106]  J. Ellwart,et al.  CD103 is a hallmark of tumor‐infiltrating regulatory T cells , 2011, International journal of cancer.

[107]  R. Hills,et al.  Expression of CD200 on AML blasts directly suppresses memory T-cell function , 2012, Leukemia.

[108]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[109]  Malcolm J. McConville,et al.  MR1 presents microbial vitamin B metabolites to MAIT cells , 2012, Nature.

[110]  J. Castle,et al.  Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.

[111]  R. Hills,et al.  Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells , 2012, Leukemia.

[112]  D. McNeel,et al.  The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer , 2013, Cancer Immunology, Immunotherapy.

[113]  R. Scolyer,et al.  Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[115]  Michael Y. Gerner,et al.  Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes. , 2012, Immunity.

[116]  B. Thaci,et al.  Recent developments on immunotherapy for brain cancer , 2012, Expert opinion on emerging drugs.

[117]  Natalie L. Catlett,et al.  Reverse causal reasoning: applying qualitative causal knowledge to the interpretation of high-throughput data , 2013, BMC Bioinformatics.

[118]  L. Lanier,et al.  Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. , 2012, Blood.

[119]  R. Carstens,et al.  Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors , 2012, Proceedings of the National Academy of Sciences.

[120]  T. Rapoport,et al.  Mechanisms of Sec61/SecY-mediated protein translocation across membranes. , 2012, Annual review of biophysics.

[121]  Yvonne McGrath,et al.  Monoclonal TCR-redirected tumor cell killing , 2012, Nature Medicine.

[122]  T. Curiel,et al.  Targeting regulatory T cells , 2012, Targeted Oncology.

[123]  C. Mauri,et al.  Immune regulatory function of B cells. , 2012, Annual review of immunology.

[124]  G. Sauter,et al.  High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. , 2013, European journal of cancer.

[125]  Antonina Rait,et al.  Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[126]  L. Southerland,et al.  VIPhyb, an Antagonist of Vasoactive Intestinal Peptide Receptor, Enhances Cellular Antiviral Immunity in Murine Cytomegalovirus Infected Mice , 2013, PloS one.

[127]  D. Reker,et al.  Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response , 2013, Cancer Immunology, Immunotherapy.

[128]  L. Antonioli,et al.  Immunity, inflammation and cancer: a leading role for adenosine , 2013, Nature Reviews Cancer.

[129]  Andrea Bertotti,et al.  Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.

[130]  Joshua F. McMichael,et al.  DGIdb - Mining the druggable genome , 2013, Nature Methods.

[131]  D. Menendez,et al.  Interactions between the tumor suppressor p53 and immune responses , 2013, Current opinion in oncology.

[132]  N. Lamond,et al.  Drug-induced subacute cutaneous lupus erythematosus associated with nab-paclitaxel therapy. , 2013, Current oncology.

[133]  T. Elliott,et al.  Induction of Protective Antitumor Immunity through Attenuation of ERAAP Function , 2013, The Journal of Immunology.

[134]  L. Khawli,et al.  Generation of tumor-targeted antibody-CpG conjugates. , 2013, Journal of immunological methods.

[135]  B. Jakobsen,et al.  Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells , 2013, Oncoimmunology.

[136]  D. Speiser.  Hit parade for adoptive cell transfer therapy: the best T cells for superior clinical responses. , 2013, Cancer discovery.

[137]  Jérôme Galon,et al.  The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. , 2013, Immunity.

[138]  Courtney Humphries,et al.  Adoptive cell therapy: Honing that killer instinct , 2013, Nature.

[139]  Dung-Tsa Chen,et al.  Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer , 2013, Cancer Immunology, Immunotherapy.

[140]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[141]  E. Griffiths,et al.  SGI-110: DNA Methyltransferase Inhibitor Oncolytic. , 2013, Drugs of the future.

[142]  G. Adema,et al.  Sweet escape: sialic acids in tumor immune evasion. , 2014, Biochimica et biophysica acta.

[143]  Charlotte Clark,et al.  Basal Cell Carcinoma: An Evidence-Based Treatment Update , 2014, American Journal of Clinical Dermatology.

[144]  Sean C. Bendall,et al.  Multiplexed ion beam imaging of human breast tumors , 2014, Nature Medicine.

[145]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[146]  D. Radisky,et al.  Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer , 2014, Oncotarget.

[147]  Paolo A Ascierto,et al.  The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 , 2014, Journal of Translational Medicine.

[148]  Inchul Lee.  Critical pathogenic steps to high risk Helicobacter pylori gastritis and gastric carcinogenesis. , 2014, World journal of gastroenterology.

[149]  Sebastian Amigorena,et al.  Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. , 2014, Cancer cell.

[150]  J. Wargo,et al.  Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation , 2014, The Journal of Immunology.

[151]  N. Nagarajan,et al.  Monitoring peptide processing for MHC class I molecules in the endoplasmic reticulum. , 2014, Current opinion in immunology.

[152]  S. Sleijfer,et al.  Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. , 2014, Cancer treatment reviews.

[153]  J. Deckert,et al.  SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies , 2014, Clinical Cancer Research.

[154]  John A. Dagata,et al.  A Nanoparticle Carrying the p53 Gene Targets Tumors Including Cancer Stem Cells, Sensitizes Glioblastoma to Chemotherapy and Improves Survival , 2014, ACS nano.

[155]  A. Krešo,et al.  Evolution of the cancer stem cell model. , 2014, Cell stem cell.

[156]  S. Rosenberg,et al.  Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions , 2014, Clinical Cancer Research.

[157]  D. Sinderen,et al.  T-cell activation by transitory neo-antigens derived from distinct microbial pathways , 2014, Nature.

[158]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[159]  P. Fisher,et al.  Molecular-genetic imaging of cancer. , 2014, Advances in cancer research.

[160]  Obi L. Griffith,et al.  SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution , 2014, PLoS Comput. Biol..

[161]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[162]  J. Taunton,et al.  An allosteric Sec61 inhibitor traps nascent transmembrane helices at the lateral gate , 2014, eLife.

[163]  Sean C. Bendall,et al.  Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis , 2015, Cell.

[164]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[165]  Harikrishna Narasimhan,et al.  Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity , 2015, Nature Communications.

[166]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[167]  F. Marincola,et al.  Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy , 2015 .

[168]  M. Spector,et al.  Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.

[169]  Y. Banz,et al.  CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis. , 2015, Leukemia research.

[170]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[171]  M. Weller,et al.  Immunosuppressive mechanisms in glioblastoma. , 2015, Neuro-oncology.

[172]  G. Trinchieri,et al.  The role of the microbiota in inflammation, carcinogenesis, and cancer therapy , 2015, European journal of immunology.

[173]  Jason B. Williams,et al.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.

[174]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[175]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[176]  T. Gajewski,et al.  The STING pathway and the T cell-inflamed tumor microenvironment. , 2015, Trends in immunology.

[177]  S. Ostrand-Rosenberg,et al.  Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. , 2015, Advances in cancer research.

[178]  Troy Guthrie,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[179]  T. Yamanaka,et al.  Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy , 2015, Oncotarget.

[180]  J. Wolchok,et al.  Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo , 2015, The Journal of Immunology.

[181]  S. Petrini,et al.  ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors. , 2015, Cancer research.

[182]  Rei Watanabe,et al.  Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells , 2015, Science Translational Medicine.

[183]  B. Paluch,et al.  Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts , 2015, Epigenetics.

[184]  George E. Katibah,et al.  Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. , 2015, Cell reports.

[185]  Richard D Moore,et al.  Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. , 2015, Annals of internal medicine.

[186]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[187]  A. Troxel,et al.  Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. , 2015, Blood.

[188]  N. Harbeck,et al.  Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade , 2015, Science Translational Medicine.

[189]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[190]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[191]  D. Ganea,et al.  The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases , 2015, Acta physiologica.

[192]  Mark A Rosenberg,et al.  Image guided cryoablation of cancer with intra-tumoral injection of anti-CTLA-4 and PD-1 immune check-point inhibitors , 2015, Journal of Immunotherapy for Cancer.

[193]  S. Voss,et al.  A novel RNA‐based adjuvant combines strong immunostimulatory capacities with a favorable safety profile , 2015, International journal of cancer.

[194]  K. Nelson.  An Update on the Status of Current Research on the Mammalian Microbiome. , 2015, ILAR journal.

[195]  Yu Shyr,et al.  Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade , 2016, Cancer Immunology Research.

[196]  P. Hwu,et al.  Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination , 2016, Oncoimmunology.

[197]  M. Ceccarelli,et al.  Disentangling the relationship between tumor genetic programs and immune responsiveness. , 2016, Current opinion in immunology.

[198]  Matheus C. Bürger,et al.  Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy , 2016, Nature.

[199]  J. Wagner,et al.  CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT , 2015, Leukemia.

[200]  P. Hegde,et al.  Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[201]  O. Straume,et al.  Abstract 566: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy , 2016 .

[202]  J. Lohmueller,et al.  Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential , 2016, Scientific Reports.

[203]  Douglas B. Johnson,et al.  Systems immune monitoring in cancer therapy. , 2016, European journal of cancer.

[204]  A. Mangraviti,et al.  Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium , 2016, Journal of immunology research.

[205]  J. C. Love,et al.  PD-1 marks dysfunctional regulatory T cells in malignant gliomas. , 2016, JCI insight.

[206]  J. Nemunaitis,et al.  Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[207]  Gwendoline Gros,et al.  TGFβ Signaling Intersects with CD103 Integrin Signaling to Promote T-Lymphocyte Accumulation and Antitumor Activity in the Lung Tumor Microenvironment. , 2016, Cancer research.

[208]  C. Melief,et al.  Vaccines for established cancer: overcoming the challenges posed by immune evasion , 2016, Nature Reviews Cancer.

[209]  J. Soria,et al.  Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. , 2016, JAMA dermatology.

[210]  M. Fassan,et al.  The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome , 2016, Oncoimmunology.

[211]  R. Berger,et al.  Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[212]  J. Utikal,et al.  Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. , 2016, European journal of cancer.

[213]  S. Rosenberg,et al.  Prospects for gene-engineered T cell immunotherapy for solid cancers , 2016, Nature Medicine.

[214]  R. Califf,et al.  Real-World Evidence - What Is It and What Can It Tell Us? , 2016, The New England journal of medicine.

[215]  D. Bar-Sagi,et al.  IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. , 2016, Cancer discovery.

[216]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[217]  C. Kiparissides,et al.  PLGA nanoparticles modified with a TNFα mimicking peptide, soluble Leishmania antigens and MPLA induce T cell priming in vitro via dendritic cell functional differentiation. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[218]  J. L. Santos,et al.  Continuous Production of Discrete Plasmid DNA-Polycation Nanoparticles Using Flash Nanocomplexation. , 2016, Small.

[219]  Ryan L. Kelly,et al.  Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses , 2016, Nature Medicine.

[220]  G. Fromm,et al.  Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination , 2016, Cancer Immunology Research.

[221]  P. Harari,et al.  In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. , 2016, Cancer research.

[222]  E. Buchbinder,et al.  CTLA-4 and PD-1 Pathways , 2016, American Journal of Clinical Oncology.

[223]  P. Vaupel,et al.  Hypoxia-Driven Adenosine Accumulation: A Crucial Microenvironmental Factor Promoting Tumor Progression. , 2016, Advances in experimental medicine and biology.

[224]  M. Sabatino,et al.  Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. , 2016, Blood.

[225]  C. Sautès-Fridman,et al.  Tertiary lymphoid structures, drivers of the anti‐tumor responses in human cancers , 2016, Immunological reviews.

[226]  Yi Xiao,et al.  Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer , 2016, Medicine.

[227]  R. Levy,et al.  In Situ Vaccination with a TLR9 Agonist and Anti-OX40 Antibody Leads to Tumor Regression and Induces Abscopal Responses in Murine Lymphoma , 2016 .

[228]  M. Vetizou,et al.  Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. , 2016, Immunity.

[229]  Z. Trajanoski,et al.  Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.

[230]  I. Frahm,et al.  TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer , 2016, Clinical Cancer Research.

[231]  Yan Cui,et al.  Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment , 2016, International journal of molecular sciences.

[232]  J. Radford.  Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.

[233]  S. Grupp,et al.  Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies , 2016, Science Translational Medicine.

[234]  Hao Jiang,et al.  SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide , 2016, Leukemia.

[235]  Yong-jian Jiang,et al.  Role of immune cells in pancreatic cancer from bench to clinical application , 2016, Medicine.

[236]  R. Levy,et al.  Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody , 2016, Clinical Cancer Research.

[237]  F. Ginhoux,et al.  Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. , 2016, Immunity.

[238]  D. McNeel,et al.  Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells , 2017, Cancer Immunology Research.

[239]  Peng-fei Wang,et al.  Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis , 2017, Front. Pharmacol..

[240]  S. Chandarlapaty,et al.  Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody , 2017, Oncoimmunology.

[241]  G. Lamberti,et al.  Institutional Animal Care and Use Committee , 2017 .

[242]  D. Carbone,et al.  First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer , 2017 .

[243]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[244]  R. Houot,et al.  Intratumoral immunotherapy: using the tumor as the remedy , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[245]  Caroline Schenkel,et al.  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[246]  M. Nishio,et al.  Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy. , 2017, Anticancer research.

[247]  R. Bourgon,et al.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.

[248]  J. Taube,et al.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.

[249]  Wei Zhang,et al.  Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. , 2017, Cell reports.

[250]  C. Drake,et al.  Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells , 2017, Cancer Immunology Research.

[251]  Jennifer G. Abelin,et al.  Mass Spectrometry Profiling of HLA‐Associated Peptidomes in Mono‐allelic Cells Enables More Accurate Epitope Prediction , 2017, Immunity.

[252]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[253]  E. Plimack,et al.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.

[254]  R. Emerson,et al.  Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells , 2017, Cancer Immunology Research.

[255]  P. Sharma,et al.  Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[256]  N. Chaput,et al.  Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[257]  N. Tinari,et al.  Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally , 2017, The Journal of Immunology.

[258]  C. Drake,et al.  Myeloid‐derived cells in prostate cancer progression: phenotype and prospective therapies , 2017, Journal of leukocyte biology.

[259]  D. Ribatti.  The concept of immune surveillance against tumors: The first theories , 2016, Oncotarget.

[260]  Nicolai J. Birkbak,et al.  Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors , 2017, Immunity.

[261]  J. Weiss,et al.  Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer , 2017, Proceedings of the National Academy of Sciences.

[262]  K. Vermeire,et al.  Inhibitors of protein translocation across membranes of the secretory pathway: novel antimicrobial and anticancer agents , 2018, Cellular and Molecular Life Sciences.

[263]  S. Lade,et al.  Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer , 2017, PloS one.

[264]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[265]  A. Ribas,et al.  Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) , 2017, The Lancet.

[266]  yang-xin fu,et al.  Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy , 2017, Cellular and Molecular Immunology.

[267]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[268]  Patrick Danaher,et al.  Gene expression markers of Tumor Infiltrating Leukocytes , 2016, Journal of Immunotherapy for Cancer.

[269]  E. Frenkel,et al.  Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients , 2017, Neoplasia.

[270]  C. Shi,et al.  PD‐1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’ , 2017, Histopathology.

[271]  P. Lowenstein,et al.  Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[272]  K. Emancipator,et al.  Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[273]  Peisheng Zhang,et al.  Resident memory T cells in the skin mediate durable immunity to melanoma , 2017, Science Immunology.

[274]  M. Fotin‐Mleczek,et al.  This information is current as Effects Triggering TLR-and RLH-Dependent Virus-Specific Vaccine Responses by Locally A New RNA-Based Adjuvant Enhances , 2017 .

[275]  Wei Zhao,et al.  Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma , 2017, Front. Pharmacol..

[276]  J. Orange,et al.  Quantitative Imaging Approaches to Study the CAR Immunological Synapse. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[277]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[278]  Tressa Hood,et al.  Immune gene expression profiling in children and adults with acute myeloid leukemia identifies distinct phenotypic patterns , 2017 .

[279]  M. Burbridge,et al.  Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies , 2017, Current Oncology Reports.

[280]  Je-Keun Rhee,et al.  Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types , 2017, Cancer Immunology Research.

[281]  Feng Zhang,et al.  Identification of essential genes for cancer immunotherapy , 2017, Nature.

[282]  John G. Doench,et al.  In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target , 2017, Nature.

[283]  David M. Woods,et al.  Predictors of responses to immune checkpoint blockade in advanced melanoma , 2017, Nature Communications.

[284]  B. Rath,et al.  Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity , 2017, Expert opinion on biological therapy.

[285]  J. Boike,et al.  Severe Esophagitis and Gastritis from Nivolumab Therapy , 2017, ACG case reports journal.

[286]  E. Bellon,et al.  Protein S100A8/A9: A Potential New Biomarker for Pancreatic Diseases , 2017 .

[287]  D. Bose.  cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response , 2017, International journal of molecular sciences.

[288]  Jason B. Williams,et al.  The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment , 2017, The Journal of experimental medicine.

[289]  Hannah C. Beird,et al.  Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma , 2017, npj Genomic Medicine.

[290]  F. Marincola,et al.  Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis , 2017, Oncoimmunology.

[291]  Benjamin D. Greenbaum,et al.  Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses , 2017, Cell.

[292]  B. Krippendorff,et al.  Interstitial IgG antibody pharmacokinetics assessed by combined in vivo‐ and physiologically‐based pharmacokinetic modelling approaches , 2017, The Journal of physiology.

[293]  A. Rudensky,et al.  Stability and function of regulatory T cells expressing the transcription factor T-bet , 2017, Nature.

[294]  R. DiPaolo,et al.  Regulation of Gastric Carcinogenesis by Inflammatory Cytokines , 2017, Cellular and molecular gastroenterology and hepatology.

[295]  O. Lantz,et al.  Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells , 2018, Cell.

[296]  C. Ager,et al.  Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy , 2018, The Journal of clinical investigation.

[297]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[298]  B. Ueberheide,et al.  Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs , 2018, Cancer Immunology Research.

[299]  L. Galluzzi,et al.  Cytosolic DNA Sensing in Organismal Tumor Control. , 2018, Cancer Cell.

[300]  Z. Zeng,et al.  Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities , 2018, Molecular Cancer.

[301]  Merrick I Ross,et al.  Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma , 2018, Nature Medicine.

[302]  P. Lowenstein,et al.  Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy. , 2016, Clinical immunology.

[303]  Steven J. M. Jones,et al.  Pathogenic Germline Variants in 10,389 Adult Cancers. , 2018, Cell.

[304]  Camille Stephan-Otto Attolini,et al.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.

[305]  A. Hemminki,et al.  Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus , 2018, Molecular therapy oncolytics.

[306]  P. Ascierto,et al.  Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[307]  Chengzhong Ye,et al.  Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis , 2018, Nature Medicine.

[308]  J. Castle,et al.  Actively personalized vaccination trial for newly diagnosed glioblastoma , 2018, Nature.

[309]  D. Torigian,et al.  Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. , 2018, Gastroenterology.

[310]  Eytan Ruppin,et al.  Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma , 2018, Nature Medicine.

[311]  J. Mulé,et al.  Suppression of STING Signaling through Epigenetic Silencing and Missense Mutation Impedes DNA-Damage Mediated Cytokine Production , 2018, Oncogene.

[312]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[313]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[314]  E. Chang,et al.  Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor , 2018, Oncoimmunology.

[315]  Tressa Hood,et al.  Capturing the complexity of the immune microenvironment of acute myeloid leukemia with 3D biology technology. , 2018 .

[316]  V. Velculescu,et al.  Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[317]  Paul J. Hoover,et al.  Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma , 2018, Cell.

[318]  V. Engelhard,et al.  Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma , 2018, Oncoimmunology.

[319]  C. Jobin,et al.  Microbiota and cancer immunotherapy: in search of microbial signals , 2018, Gut.

[320]  J. Kirkwood,et al.  Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma , 2018, Clinical Trials.

[321]  L. Stern,et al.  Molecular pathways for antigenic peptide generation by ER aminopeptidase 1. , 2019, Molecular immunology.

[322]  C. Bettegowda,et al.  Current state of immunotherapy for glioblastoma , 2018, Nature Reviews Clinical Oncology.

[323]  Michael L. Wang,et al.  T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[324]  Francesco Ferrari,et al.  High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors , 2018, The Journal of experimental medicine.

[325]  P. Harari,et al.  Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites , 2018, Cancer Immunology Research.

[326]  M. Bissell,et al.  hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis , 2018, Oncogene.

[327]  A. Hemminki,et al.  TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade , 2018, Oncoimmunology.

[328]  F. Marincola,et al.  Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA) , 2018, Journal of Immunotherapy for Cancer.

[329]  Sean C. Bendall,et al.  A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging , 2018, Cell.

[330]  L. Bazhenova,et al.  New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1 , 2018, Therapeutic advances in respiratory disease.

[331]  N. D. de Miranda,et al.  Cancer immunotherapy: broadening the scope of targetable tumours , 2018, Open Biology.

[332]  C. Van Waes,et al.  Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms , 2017, Oncoimmunology.

[333]  Henry W. Long,et al.  A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing , 2018, Science.

[334]  E. Le Chatelier,et al.  Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.

[335]  G. MacBeath,et al.  ABP-100: A tetravalent bispecific T-cell engaging antibody for HER2+ solid tumors. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[336]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[337]  Aleksey K. Molodtsov,et al.  Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity , 2018, Front. Immunol..

[338]  M. Berger,et al.  Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy , 2018, Science.

[339]  J. Lai,et al.  An Unusual Case of Gastritis in One Patient Receiving PD-1 Blocking Therapy: Coexisting Immune-Related Gastritis and Cytomegaloviral Infection , 2018, Gastroenterology research.

[340]  J. Gartner,et al.  Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. , 2018, JCI insight.

[341]  R. Rosell,et al.  Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC) , 2018, Therapeutic advances in medical oncology.

[342]  R. Rabadán,et al.  Quantitative Analysis of Immune Infiltrates in Primary Melanoma , 2018, Cancer Immunology Research.

[343]  W. Weichert,et al.  A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy , 2018, Oncotarget.

[344]  R. Coffman,et al.  SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. , 2018, Cancer discovery.

[345]  Ehsan Kazemi,et al.  Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images , 2017, bioRxiv.

[346]  Yang Feng,et al.  CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL , 2017, Nature Medicine.

[347]  G. Cavet,et al.  Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens. , 2017, Clinical immunology.

[348]  R. Gelber,et al.  Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. , 2018, The Lancet. Oncology.

[349]  F. Di Virgilio,et al.  Extracellular ATP and P2 purinergic signalling in the tumour microenvironment , 2018, Nature Reviews Cancer.

[350]  N. Bercovici,et al.  Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment , 2018, Proceedings of the National Academy of Sciences.

[351]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[352]  I. Ong,et al.  TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8+ T Cells , 2018, Cancer Immunology Research.

[353]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[354]  Cheng Song,et al.  MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC , 2018, Cellular Physiology and Biochemistry.

[355]  J. Taube,et al.  Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[356]  R. Emerson,et al.  Radiotherapy induces responses of lung cancer to CTLA-4 blockade , 2018, Nature Medicine.

[357]  E. Soule,et al.  Percutaneous ablative cryoimmunotherapy for micrometastaic abscopal effect: No complications. , 2018, Cryobiology.

[358]  J. Webb,et al.  Resident Memory-Like Tumor-Infiltrating Lymphocytes (TILRM): Latest Players in the Immuno-Oncology Repertoire , 2018, Front. Immunol..

[359]  Michele A. Busby,et al.  Supplementary Materials for Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification , 2018 .

[360]  L. Gordon,et al.  In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. , 2018, Cancer discovery.

[361]  Riyue Bao,et al.  The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.

[362]  F. Marincola,et al.  The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer , 2018, British Journal of Cancer.

[363]  R. Sullivan,et al.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[364]  M. Shah,et al.  Evaluation of intratumoral T cells in biopsies from advanced gastric cancer patients treated with andecaliximab and nivolumab. , 2019, Journal of Clinical Oncology.

[365]  Robert Langer,et al.  Delivery technologies for cancer immunotherapy , 2019, Nature Reviews Drug Discovery.

[366]  E. Charpentier,et al.  Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma , 2019, Blood Cancer Journal.

[367]  S. Murphy,et al.  Novel tetravalent bispecific T-cell engaging antibodies for cancer immunotherapy. , 2019, Journal of Clinical Oncology.

[368]  Haoyang Zeng,et al.  DeepLigand: accurate prediction of MHC class I ligands using peptide embedding , 2019, Bioinform..

[369]  D. Irvine,et al.  Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy , 2019, Science Translational Medicine.

[370]  J. Larkin,et al.  Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic stage IV melanoma , 2019 .

[371]  Z. Zeng,et al.  Natural killer group 2D receptor and its ligands in cancer immune escape , 2019, Molecular Cancer.

[372]  M. Hurwitz,et al.  Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. , 2019, Journal of Clinical Oncology.

[373]  M. Shah,et al.  A phase II, open-label, randomized study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma. , 2017, Journal of Clinical Oncology.

[374]  A. Roussel,et al.  Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity , 2019, Cell.

[375]  M. Beksac,et al.  A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). , 2019, Journal of Clinical Oncology.

[376]  F. Marincola,et al.  Genomic landscape of tumor-host interactions with differential prognostic and predictive connotations , 2019, bioRxiv.

[377]  B. Bednarz,et al.  Preclinical Characterization of 86/90Y-NM600 in a Variety of Murine and Human Cancer Tumor Models , 2019, The Journal of Nuclear Medicine.

[378]  C. Morrison,et al.  Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma , 2019, Clinical Cancer Research.

[379]  G. Linette,et al.  A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma , 2019, Nature Medicine.

[380]  F. Hodi,et al.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. , 2018, Endocrine reviews.

[381]  S. Kaul,et al.  Abstract LB-268: Assessment of flat dosing strategy for INCMGA00012 in patients with advanced tumors , 2019, Experimental and Molecular Therapeutics.

[382]  F. Prósper,et al.  The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma , 2019, Clinical Cancer Research.

[383]  Jiani C Yin,et al.  Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer , 2019, Clinical Cancer Research.

[384]  K. Ikeo,et al.  Clonal analysis revealed functional heterogeneity in cancer stem-like cell phenotypes in uterine endometrioid adenocarcinoma. , 2019, Experimental and molecular pathology.

[385]  M. Shah,et al.  Exploratory evaluation of baseline tumor biomarkers and their association with response and survival in patients with previously treated advanced gastric cancer treated with andecaliximab combined with nivolumab versus nivolumab. , 2019, Journal of Clinical Oncology.

[386]  T. Chan,et al.  The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy , 2019, Nature Reviews Cancer.

[387]  A. Hotson,et al.  Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers. , 2019, Journal of Clinical Oncology.

[388]  D. Plichta,et al.  A defined commensal consortium elicits CD8 T cells and anti-cancer immunity , 2019, Nature.

[389]  M. Witjes,et al.  Abstract CT018: Image guided surgery for tumor agnostic detection of solid tumors using the pH activated micellar imaging agent ONM-100: The Shine study , 2019, Clinical Trials.

[390]  M. Sznol,et al.  Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR–anti-CD3, in patients with advanced melanoma. , 2019, Journal of Clinical Oncology.

[391]  R. Sullivan,et al.  Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition , 2019, Cancer Immunology, Immunotherapy.

[392]  The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant , 2019, Scientific Reports.

[393]  B. van der Vegt,et al.  Abstract P2-14-29: Image guided surgery for tumor detection in breast cancer using the PH activated micellar tracer ONM-100: The SHINE study , 2019, Poster Session Abstracts.

[394]  G. Pinkus,et al.  Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity , 2019, Cell.

[395]  G. Kang,et al.  Prognostic significance of CD103+ immune cells in solid tumor: a systemic review and meta-analysis , 2019, Scientific Reports.

[396]  J. Gartner,et al.  Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. , 2019, Cancer discovery.

[397]  B. Helmink,et al.  The microbiome, cancer, and cancer therapy , 2019, Nature Medicine.

[398]  P. Moore,et al.  Abstract CT085: Pharmacodynamic correlates in a phase I study of INCMGA00012, a PD-1 antagonistic monoclonal antibody , 2019, Clinical Trials.

[399]  Helen E. Parkinson,et al.  The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019 , 2018, Nucleic Acids Res..

[400]  Hiromasa Morikawa,et al.  PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer , 2019, Proceedings of the National Academy of Sciences.

[401]  David C. Smith,et al.  Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab , 2019, JAMA oncology.

[402]  G. Ciliberto,et al.  Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth , 2019, Journal of Experimental & Clinical Cancer Research.

[403]  J. Flickinger,et al.  Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients , 2019, Journal of Immunotherapy for Cancer.

[404]  M. Witjes,et al.  Image-guided surgery for tumor agnostic detection of solid tumors using the pH-activated micellar imaging agent ONM-100. , 2019, Journal of Clinical Oncology.

[405]  Ash A. Alizadeh,et al.  Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.

[406]  C. Bokemeyer,et al.  Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216). , 2020 .